SARASOTA, Florida, March 1, 2016 /PRNewswire/ -- Rock Creek Pharmaceuticals, Inc., (OTCQB: RCPI), a clinical stage drug development company focused on the application of its lead compound being developed to treat acute and chronic inflammatory conditions, announced today that the Company has retained one of the world's leading experts in clinical dermatology and research, as a scientific advisor, who will advise, enhance and assist with the Company's inflammatory skin disease drug development program.
Logo - http://photos.prnewswire.com/prnh/20150617/223737LOGO
The Company has appointed and entered into a scientific consultancy agreement with Professor Alan Menter MD, Chief of Dermatology, Baylor University Medical Center, Dallas, Texas.
Dr. Michael Mullan, (MBBS, PhD), Chairman and Chief Executive Officer of Rock Creek Pharmaceuticals, highlighted, "We are honored that Professor Menter has agreed to work with us as a scientific advisor. He is recognized as one of the top Psoriasis experts in the world and should help us validate our approach utilizing a drug with a new mechanism of action for the treatment of inflammatory skin diseases. His unmatched scientific knowledge and deep clinical experience will be invaluable to the advancement of our clinical development program."
Dr. Alan Menter was born in England and is a graduate of the Medical School of the University of Witwatersrand, South Africa. He completed his dermatology residency at Pretoria General Hospital at the University of Pretoria, South Africa, and two fellowships in London at Guy's Hospital and St. John's Hospital for Diseases of the Skin.
A fellowship with the University of Texas Southwestern Medical Center in Dallas brought Dr. Menter to the United States. Since then, he has held several positions within the UT and Baylor University systems. In 1992, he was appointed chairman of the Division of Dermatology at Baylor University Medical Center, a position he still holds. In 2007, he was appointed director of the Baylor Research Center and in 2010, Program Director of the newly formed Dermatology Residency Program at Baylor University Medical Center.
Dr. Menter has a long-held interest in psoriasis from clinical and research perspectives. He co-authored a paper describing the first discovery of a gene for psoriasis, published in Science in 1994. His research on psoriasis has examined everything from ultraviolet phototherapy and the use of biologics to the mapping of genetic patterns to predict if a person is at risk of developing psoriasis.
In August 2004, Dr. Menter helped found the International Psoriasis Council to raise international awareness of psoriasis as a serious autoimmune disease that can significantly impact quality of life. His clinical practice includes more than 1,600 patients on systemic and biologic therapy and phototherapy.
Dr. Menter held the position of clinical director of the National Psoriasis Foundation Gene Bank from 1996 to 2002. His resume lists over 350 publications in medical and dermatology journals plus four books and multiple book chapters. He serves as a member of the editorial board for many medical journals, including the Journal of Clinical Dermatology and Clinical and Experimental Dermatology. He is Chair of Research for Dermatology at Baylor Research Institute, Principle Faculty at Texas A&M University Health Science Center, as well as clinical professor of dermatology at the University of Texas Southwestern Medical School in Dallas.
Dr. Menter has been listed in the Best Doctors in America since 1994 and Who's Who in Medicine and Healthcare since 1996.
About Anatabine Citrate:
Rock Creek Pharmaceuticals' compound is a small molecule, cholinergic agonist that exhibits anti-inflammatory pharmacological characteristics, distinct from other anti-inflammatory drugs available such as biologics, steroids and non-steroidal anti-inflammatories. The Company's lead compound has been investigated extensively in pre-clinical (in vitro and in vivo) studies resulting in several peer reviewed and published scientific journal articles, covering models of multiple sclerosis, Alzheimer's disease, and autoimmune thyroiditis. All these studies demonstrated the anti-inflammatory effects of the Company's compound. In addition, the Company's compilation of human exposure, safety and tolerability data, has provided important insights for ongoing clinical and regulatory pharmaceutical development.
About Rock Creek Pharmaceuticals, Inc.:
Rock Creek Pharmaceuticals, Inc. is an emerging drug development company focused on the discovery, development and commercialization of new drugs, formulations and compounds that provide therapies for chronic and acute inflammatory diseases.
For more information, visit: http://www.rockcreekpharmaceuticals.com
Forward Looking Statements:
Certain statements contained in this release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to statements identified by words such as "believes," "expects," "anticipates," "estimates," "intends," "plans," "targets," "projects" and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, failure to obtain sufficient capital resources to fund our development program and operations, results of clinical trials and/or other studies, the challenges inherent in new product development initiatives, including the continued development and approval of anti-inflammatory drug candidates, the effect of any competitive products, our ability to license and protect our intellectual property, our significant payables, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, potential litigation by or against us, any governmental review of our products or practices, pending litigation matters, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our annual report on Form 10-K for the fiscal year ended December 31, 2014 filed on March 12, 2015. We undertake no duty to update any forward-looking statement or any information contained in this press release or in other public disclosures at any time.
CONTACT:
Investor Contact:
PCG Advisory Group
Stephanie Prince
646.762.4518
sprince@pcgadvisory.com
Media Contact:
PCG Advisory Group
Sean Leous
646 863 8998
sleous@pcgadvisory.com
Company Contact:
Rock Creek Pharmaceuticals, Inc.
2040 Whitfield Ave. Suite 300
Sarasota Florida, 34243
1-844-727-0727
IR@rockcreekpharma.com
Share this article